Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interferon-alpha and auto-immunity].

T Papo1

  • 1Service de médecine interne, hôpital Bichat, 46, rue Henri-Huchard, 75877 Paris, France. thomas.papo@bch.ap-hop-paris.fr

La Revue De Medecine Interne
|December 17, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcome and prognosis of isolated carotid vasculitis.

Journal of autoimmunity·2024
Same author

[Update on Susac syndrome].

La Revue de medecine interne·2021
Same author

Are script concordance tests suitable for the assessment of undergraduate students? A multicenter comparative study.

La Revue de medecine interne·2020
Same author

[Post-acute and rehabilitation care in young patients with multiple comorbidities: An observational study].

La Revue de medecine interne·2020
Same author

[Haemothorax revealing thoracic endometriosis].

La Revue de medecine interne·2020
Same author

[Association between psychiatric comorbidities and hospital length of stay in post-emergency internal medicine patients].

La Revue de medecine interne·2020
Same journal

[Abdominal pain, fever and arthralgia in a 49-year-old woman].

La Revue de medecine interne·2026
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

[Diagnostic evaluation for suspected polycythemia].

La Revue de medecine interne·2026
Same journal

Heart involvements in systemic sclerosis beyond pulmonary hypertension: From conduction, rhythm and function defects to coronary artery disease.

La Revue de medecine interne·2026
Same journal

[Acute intermittent porphyria: When diagnostic errance jeopardizes patient health].

La Revue de medecine interne·2026
Same journal

Autosomal dominant polycystic kidney disease: Current perspectives in 2026.

La Revue de medecine interne·2026
See all related articles

Recombinant interferon alpha (IFN) can trigger autoimmune disorders, not cause them anew. Caution is advised when using IFN as an immunomodulator due to potential autoimmune side effects.

Area of Science:

  • Immunology
  • Cytokine biology
  • Autoimmunity

Context:

  • Interferon alpha (IFN) is a cytokine crucial for cellular immunity, promoting dendritic cell differentiation and the TH1 pathway.
  • Autoimmune side effects of recombinant IFN are dose- and pathology-dependent, ranging from autoantibody development to overt diseases like systemic lupus.
  • The incidence of IFN-induced thyroiditis is debated but appears low (<1%) in hepatologic studies with low-dose IFN.

Purpose:

  • To investigate the role of endogenous interferon alpha (IFN) in experimental autoimmune models and human diseases.
  • To evaluate the potential iatrogenic risks of using IFN as a therapeutic agent.

Summary:

  • Recombinant IFN can induce autoantibodies and autoimmune diseases, with thyroiditis being the most common.

Related Experiment Videos

  • Pre-existing autoimmunity related to the treated condition can complicate IFN's side effect profile.
  • Antigenic targets of IFN-induced autoantibodies are diverse, including blood cells, coagulation factors, hormones, and intracellular components.

    • Impact:

    • Recombinant alpha interferon acts as a trigger for autoimmune disorders rather than a de novo inducer.
    • The use of IFN as an immunomodulator necessitates careful consideration due to its potential to exacerbate or induce autoimmunity.